淀粉样变治疗学研究的最新进展.pdfVIP

172 MODERN ONCOLOGY, Jan2011, VOI19, NO01 clinical outcom e of patients w ith advanced nonsm all cell lung - 6 as a predictive m arker of radiation pneum onitis in patients cancer treated w ith epiderm al grow th factor receptor tyrosine ki w ith breast- conservation therapy[ J]. Int J Clin Onco,l 2004, 9 nase inhibitors[ J]. Int J Cancer, 200 , 122( 11) : 2612- 2620. ( 6) : 49 - 502. [ 17] Ohara G, Kurishmi a K, Ishikaw a H, et al. KL - 6 and poor [ 20] Matsuno Y, Satoh H, Ishikaw a H, et al. Smi ultaneous m easure prognosis in NSCLC patients treated w ith gefitinib [ J]. Lung m ents ofKL- 6 and SP- D in patients undergoing thoracic radio Cancer, 200 , 59( 1) : 1- 7. therapy[ J]. MedOncol, 2006, 23( 1) : 75- 2. [ 1 ] M atsumura K, N iki I, T ianH, et a.l Radiomi munoscintigraphy of [ 21] Kong FM, Ao X, W ang L, et al. The use of blood biom arkers to pancreatic cancer in tum or- bearing athym ic nude m ice u sing predict radiation lung tox icity: a potential strategy to individualize ( 99m) technetium - labeled anti- KL - 6 /MUC1 antibody [ J]. thoracic radiation therapy[ J]. CancerControl, 200 , 15( 2) : 140 RadiatM ed, 200 , 26( 3) : 133- 139. - 150. [ 19] TokiyaR, H iratsuka J, Yoshida K, et a.l Eva luation of serum KL (编校: 田媛) 淀粉样变治疗学研究的最新进展 王学文 Recentprogress of research on therapeutics of amyloidosis WANG Xue- w en D ep artment of H ematology, N anjing GeneralH osp ital of N anjingM ilitary Command, Nanjing 210002, China. A bstractDuring the past 10 to 15 years, there has been substantial progress in developing new treatments for the system ic amyloidosis. These advances have mi proved patient ou tcom es but have also raised new questionsw ith direct clin ical mi plications. For exam ple, developm ent of less intensive treatm